Oxadiazolone‐Triazole Derivatives as a New Scaffold for Modulation of Angiotensin II‐Induced Vascular Contraction
ChemMedChem · 2026
DOI: 10.1002/cmdc.70460 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Larissa F L Ferreira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Fundamental Chemistry, Federal University of Pernambuco (UFPE), Recife, Brazil. Hauptthemen laut MEDLINE: Triazoles, Oxadiazoles, Angiotensin II, Angiotensin II Type 1 Receptor Blockers. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco, Universidade Federal de Pernambuco.
Abstract (Originalsprache)
In this study, a series of novel angiotensin II type 1 receptor (AT 1 R) antagonist candidates containing the 1,2,4‐oxadiazol‐5‐one nucleus and a 1,2,3‐triazole moiety was designed, synthesized, and evaluated. Compounds 7a – j were obtained via a semiconvergent synthetic route employing copper‐catalyzed azide–alkyne cycloaddition (click chemistry), yielding the target molecules in moderate to good yields. Biological activity was assessed through vascular reactivity assays using rat aortic rings in the presence of angiotensin II. Most compounds reduced angiotensin II‐induced contraction, consistent with a putative AT 1 receptor antagonist profile. Among them, compound 7f , bearing a methylenedioxyphenyl substituent, exhibited the most favorable biological profile within the series. The results indicate that electron‐donating groups favor activity, while strongly electron‐withdrawing substituents, such as nitro, are detrimental. Molecular docking studies predicted consistent interactions with key residues, particularly Arg167 and Tyr87, providing a plausible structural rationale for the observed biological activity. In silico ADME predictions indicated acceptable drug‐like properties, including compliance with drug‐likeness filters and a predicted bioavailability score, and no blood–brain barrier permeation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Fundamental Chemistry, Federal University of Pernambuco (UFPE), Recife, Brazil.
- Vitória Academic Centre (CAV), Federal University of Pernambuco (UFPE), Vitória de Santo Antão, Pernambuco, Brazil.
ORCID-Profile: Larissa F L Ferreira, Alice V Araújo, Janaína V Dos Anjos
Förderung
- Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco
- Universidade Federal de Pernambuco
Zitieren
APA
Ferreira, L. F. L., Vasconcelos, D. G. A., Santos, R. C. A., Ferreira, J. G., Araújo, A. V., & Anjos, J. V. D. (2026). Oxadiazolone‐Triazole Derivatives as a New Scaffold for Modulation of Angiotensin II‐Induced Vascular Contraction. ChemMedChem. https://doi.org/10.1002/cmdc.70460
Vancouver
Ferreira LFL, Vasconcelos DGA, Santos RCA, Ferreira JG, Araújo AV, Anjos JVD. Oxadiazolone‐Triazole Derivatives as a New Scaffold for Modulation of Angiotensin II‐Induced Vascular Contraction. ChemMedChem. 2026. doi:10.1002/cmdc.70460
BibTeX
@article{Ferreira2026,
author = {Ferreira, Larissa F L and Vasconcelos, Daiana G de A and Santos, Ruth C A and Ferreira, Jivaldo G and Araújo, Alice V and Anjos, Janaína V Dos},
title = {Oxadiazolone‐Triazole Derivatives as a New Scaffold for Modulation of Angiotensin II‐Induced Vascular Contraction},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70460}
}
EUVIMED